The anti-angiogenic effects of 1-furan-2-yl-3-pyridin-2-yl-propenone are mediated through the suppression of both VEGF production and VEGF-induced signaling

Vascular Pharmacology

Volumn 50, Issue 3-4, 2009, Pages 123-131

  Park, Byung Chul ^a   Park, Su Young ^a   Lee, Jong Suk ^a   Mousa, Shaker A ^b   Kim, Jong Tae ^a   Kwak, Mi Kyoung ^a   Kang, Keon Wook ^c   Lee, Eung Seok ^a   Choi, Han Gon ^a   Yong, Chul Soon ^a   Kim, Jung Ae ^a  

^a Yeungnam University   (South Korea)

^b ALBANY COLLEGE OF PHARMACY AND HEALTH SCIENCES   (United States)

^c Chosun University   (South Korea)

Author keywords

COX 2; pERK; Propenone; ROS; Tissue factor; Tumor angiogenesis

Indexed keywords

1 FURAN 2 YL 3 PYRIDIN 2 YL PROPENONE; ANGIOGENESIS INHIBITOR; CYCLOOXYGENASE 2 INHIBITOR; GELATINASE A; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; REACTIVE OXYGEN METABOLITE; THROMBOPLASTIN; TISSUE FACTOR PATHWAY INHIBITOR; UNCLASSIFIED DRUG; VASCULOTROPIN;

ANGIOGENESIS; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; ARTICLE; BLOOD CLOTTING; BREAST CANCER; CANCER CELL; CANCER CELL CULTURE; CELL INVASION; CELL PROLIFERATION; CELL STRAIN HT1080; CELL STRAIN MCF 7; CELL SURVIVAL; CHICK; CHORIOALLANTOIS; CONTROLLED STUDY; CYTOKINE PRODUCTION; DOSE RESPONSE; DRUG INHIBITION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; HUMAN UMBILICAL VEIN ENDOTHELIAL CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN PHOSPHORYLATION; UMBILICAL VEIN;

ANGIOGENESIS INHIBITORS; ANIMALS; CELLS, CULTURED; CHICK EMBRYO; ENDOTHELIAL CELLS; FEMALE; FURANS; HUMANS; LIPOPROTEINS; PREGNANCY; PROPANE; PYRIDINES; SIGNAL TRANSDUCTION; THROMBOPLASTIN; TUMOR CELLS, CULTURED; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 58549118706     PISSN: 15371891     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vph.2008.11.006     Document Type: Article

References (56)

1. Abid M.R., Kachra Z., Spokes K.C., and Aird W.C. NADPH oxidase activity is required for endothelial cell proliferation and migration. FEBS Lett. 486 (2000) 252-256
2. Auerbach R., Kubai L., Knighton D., and Folkman J. A simple procedure for the long-term cultivation of chicken embryos. Dev. Biol. 41 (1974) 391-394
3. 2 are potent inducers of vascular endothelial growth factor expression in cultured keratinocytes. J. Biol. Chem. 271 (1996) 21793-21797
4. Carmeliet P., and Jain R.K. Angiogenesis in cancer and other diseases. Nature 407 (2000) 249-257
5. Colman R.W., Pixley R.A., Sainz I.M., Song J.S., Isordia-Salas I., Muhamed S.N., Powell J.A., and Mousa Jr. S.A. Inhibition of angiogenesis by antibody blocking the action of proangiogenic high-molecular-weight kininogen. J. Thromb. Haemost. 1 (2003) 164-170
6. Colavitti R., Pani G., Bedogni B., Anzevino R., Borrello S., Waltenberger J., and Galeotti T. Reactive oxygen species as downstream mediators of angiogenic signaling by vascular endothelial growth factor receptor-2/KDR. J. Biol. Chem. 277 (2002) 3101-3108
7. Fidler I.J., Singh R.K., Yoneda J., Kumar R., Xu L., Dong Z., Bielenberg D.R., McCarty M., and Ellis L.M. Critical determinants of neoplastic angiogenesis. Cancer J. 6 (2000) S225-S236
8. Fife R.S., Stott B., and Carr R.E. Effects of a selective cyclooxygenase-2 inhibitor on cancer cells in vitro. Cancer Biol. Ther. 3 (2004) 228-232
9. FitzGerald G.A., and Patrono C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 345 (2001) 433-442
10. Flis S., Soltysiak-Pawluczuk D., Jedrych A., Jastrzebski Z., Remiszewska M., and Splawinski J. Antiangiogenic effect of sulindac sulfide could be secondary to induction of apoptosis and cell cycle arrest. Anticancer Res. 26 (2006) 3033-3041
11. Ghosh M., Wang H., Ai Y., Romeo E., Luyendyk J.P., Peters J.M., Mackman N., Dey S.K., and Hla T. COX-2 suppresses tissue factor expression via endocannabinoid-directed PPARdelta activation. J. Exp. Med. 204 (2007) 2053-2061
12. Herron G.S., Banda M.J., Clark E.J., Gavrilovic J., and Werb Z. Secretion of metalloproteinases by stimulated capillary endothelial cells. II. Expression of collagenase and stromelysin activities is regulated by endogenous inhibitors. J. Biol. Chem. 261 (1986) 2814-2818
13. Howe L.R., Chang S.H., Tolle K.C., Dillon R., Young L.J., Cardiff R.D., Newman R.A., Yang P., Thaler H.T., Muller W.J., Hudis C., Brown A.M., Hla T., Subbaramaiah K., and Dannenberg A.J. HER2/neu-induced mammary tumorigenesis and angiogenesis are reduced in cyclooxygenase-2 knockout mice. Cancer Res. 65 (2005) 10113-10119
14. Inoue H., Taba Y., Miwa Y., Yokota C., Miyagi M., and Sasaguri T. Transcriptional and posttranscriptional regulation of cyclooxygenase-2 expression by fluid shear stress in vascular endothelial cells. Arterioscler. Thromb. Vasc. Biol. 22 (2002) 1415-1420
15. Jahng Y., Zhao L.X., Moon Y.S., Basnet A., Kim E.K., Chang H.W., Ju H.K., Jeong T.C., and Lee E.S. Simple aromatic compounds containing propenone moiety show considerable dual COX/5-LOX inhibitory activities. Bioorg. Med. Chem. Lett. 14 (2004) 2559-2562
16. Jantke J., Ladehoff M., Kurzel F., Zapf S., Kim E., and Giese A. Inhibition of the arachidonic acid metabolism blocks endothelial cell migration and induces apoptosis. Acta Neurochir (Wien) 146 (2004) 483-494
17. Jones S.C. Relative thromboembolic risks associated with COX-2 inhibitors. Ann. Pharmacother. 39 (2005) 1249-1259
18. Jones M.K., Wang H., Peskar B.M., Levin E., Itani R.M., Sarfeh I.J., and Tarnawski A.S. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. Nat. Med. 5 (1999) 1418-1423
19. Kamiyama M., Pozzi A., Yang L., Debusk L.M., Breyer R.M., and Lin P.C. EP2, a receptor for PGE(2), regulates tumor angiogenesis through direct effects on endothelial cell motility and survival. Oncogene 25 (2006) 7019-7028
20. Kawamori T., Rao C.V., Seibert K., and Reddy B.S. Chemopreventive activity of celecoxib, a specific cyclooxygenase-2 inhibitor, against colon carcinogenesis. Cancer Res. 58 (1998) 409-412
21. Kim, J.A., Cho, K.B., Kim, M.R., Park, B.C., Kim, S.K., Lee, M.Y., Kang, K.W., 2008. Decreased production of vascular endothelial growth factor in adriamycin-resistant breast cancer cells. Cancer Lett. 268, 225-232.
22. Kobayashi H., Uetake H., Higuchi T., Enomoto M., and Sugihara K. JTE-522, a selective COX-2 inhibitor, inhibits growth of pulmonary metastases of colorectal cancer in rats. BMC Cancer 5 (2005) 26
23. Kroll J., and Waltenberger J. The vascular endothelial growth factor receptor KDR activates multiple signal transduction pathways in porcine aortic endothelial cells. J. Biol. Chem. 272 (1997) 32521-32527
24. Kuroki M., Voest E.E., Amano S., Beerepoot L.V., Takashima S., Tolentino M., Kim R.Y., Rohan R.M., Colby K.A., Yeo K.T., and Adamis A.P. Reactive oxygen intermediates increase vascular endothelial growth factor expression in vitro and in vivo. J. Clin. Invest. 98 (1996) 1667-1675
25. Lee E.S., Ju H.K., Moon T.C., Lee E., Jahng Y., Lee S.H., Son J.K., Baek S.H., and Chang H.W. Inhibition of nitric oxide and tumor necrosis factor-alpha (TNF-alpha) production by propenone compound through blockade of nuclear factor (NF)-kappa B activation in cultured murine macrophages. Biol. Pharm. Bull. 27 (2004) 617-620
26. Lee E.S., Park B.C., Paek S.H., Lee Y.S., Basnet A., Jin D.Q., Choi H.G., Yong C.S., and Kim J.A. Potent analgesic and anti-inflammatory activities of 1-furan-2-yl-3-pyridin-2-yl-propenone with gastric ulcer sparing effect. Biol. Pharm. Bull. 29 (2006) 361-364
27. Linderholm B.K., Lindh B., Beckman L., Erlanson M., Edin K., Travelin B., Bergh J., Grankvist K., and Henriksson R. Prognostic correlation of basic fibroblast growth factor and vascular endothelial growth factor in 1307 primary breast cancers. Clin. Breast Cancer 4 (2003) 340-347
28. Liu X.H., Kirschenbaum A., Yao S., Lee R., Holland J.F., and Levine A.C. Inhibition of cyclooxygenase-2 suppresses angiogenesis and the growth of prostate cancer in vivo. J. Urol. 164 (2000) 820-825
29. Ma L., Francia G., Viloria-Petit A., Hicklin D.J., du Manoir J., Rak J., and Kerbel R.S. In vitro procoagulant activity induced in endothelial cells by chemotherapy and antiangiogenic drug combinations: modulation by lower-dose chemotherapy. Cancer Res. 65 (2005) 5365-5373
30. Manandhar S., You A., Lee E.S., Kim J.A., and Kwak M.K. Activation of the Nrf2-antioxidant system by a novel cyclooxygenase-2 inhibitor furan-2-yl-3-pyridin-2-yl-propenone: implication in anti-inflammatory function by Nrf2 activator. J. Pharm. Pharmacol. 60 (2008) 879-887
31. Masferrer J.L., Leahy K.M., Koki A.T., Zweifel B.S., Settle S.L., Woerner B.M., Edwards D.A., Flickinger A.G., Moore R.J., and Seibert K. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 60 (2000) 1306-1311
32. Masunaga R., Kohno H., Dhar D.K., Ohno S., Shibakita M., and Kinugasa S. Cyclooxygenase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res. 6 (2000) 4064-4068
33. Neaud V., Duplantier J.G., Mazzocco C., Kisiel W., and Rosenbaum J. Thrombin up-regulates tissue factor pathway inhibitor-2 synthesis through a cyclooxygenase-2-dependent, epidermal growth factor receptor-independent mechanism. J. Biol. Chem. 279 (2004) 5200-5206
34. Oshima M., Dinchuk J.E., Kargman S.L., Oshima H., Hancock B., Kwong E., Trzaskos J.M., Evans J.F., and Taketo M.M. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 87 (1996) 803-809
35. Park B.C., Thapa D., Lee Y.S., Kwak M.K., Lee E.S., Choi H.G., Yong C.S., and Kim J.A. 1-Furan-2-yl-3-pyridin-2-yl-propenone inhibits the invasion and migration of HT1080 human fibrosarcoma cells through the inhibition of proMMP-2 activation and down regulation of MMP-9 and MT1-MMP. Eur. J. Pharmacol. 567 (2007) 193-197
36. Peterson H.I. Effects of prostaglandin synthesis inhibitors on tumor growth and vascularization. Experimental studies in the rat. Invasion Metastasis 3 (1983) 151-159
37. Rak J., Filmus J., and Kerbel R.S. Reciprocal paracrine interactions between tumour cells and endothelial cells: the 'angiogenesis progression' hypothesis. Eur. J. Cancer 32 (1996) 2438-2450
38. Ramanathan M., Giladi A., and Leibovich S.J. Regulation of vascular endothelial growth factor gene expression in murine macrophages by nitric oxide and hypoxia. Exp. Biol. Med. (Maywood) 228 (2003) 697-705
39. Reddy B.S., Rao C.V., and Seibert K. Evaluation of cyclooxygenase-2 inhibitor for potential chemopreventive properties in colon carcinogenesis. Cancer Res. 56 (1996) 4566-4569
40. Riendeau D., Percival M.D., Brideau C., Charleson S., Dubé D., Ethier D., Falgueyret J.P., Friesen R.W., Gordon R., Greig G., Guay J., Mancini J., Ouellet M., Wong E., Xu L., Boyce S., Visco D., Girard Y., Prasit P., Zamboni R., Rodger I.W., Gresser M., Ford-Hutchinson A.W., Young R.N., and Chan C.C. Etoricoxib (MK-0663): preclinical profile and comparison with other agents that selectively inhibit cyclooxygenase-2. J. Pharmacol. Exp. Ther. 296 (2001) 558-566
41. Sawaoka H., Tsuji S., Tsujii M., Gunawan E.S., Sasaki Y., and Kawano S. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Invest. 79 (1999) 1469-1477
42. Shibata A., Nagaya T., Imai T., Funahashi H., Nakao A., and Seo H. Inhibition of NF-kappaB activity decreases the VEGF mRNA expression in MDA-MB-231 breast cancer cells. Breast Cancer Res. Treat. 73 (2002) 237-243
43. Shih C.H., Ozawa S., Ando N., Ueda M., and Kitajima M. Vascular endothelial growth factor expression predicts outcome and lymph node metastasis in squamous cell carcinoma of the esophagus. Clin. Cancer Res. 6 (2000) 1161-1168
44. Spektor G., and Fuster V. Drug insight: cyclo-oxygenase 2 inhibitors and cardiovascular risk-where are we now? Nat. Clin. Pract. Cardiovasc. Med. 2 (2005) 290-300
45. Srinath P., Rao P.N., Knaus E.E., and Suresh M.R. Effect of cyclooxygenase-2 (COX-2) inhibitors on prostate cancer cell proliferation. Anticancer Res. 23 (2003) 3923-3928
46. Steffel J., Lüscher T.F., Ruschitzka F., and Tanner F.C. Cyclooxygenase-2 inhibition and coagulation. J. Cardiovasc. Pharmacol. 47 Suppl 1 (2006) S15-S20
47. Taketo M.M. COX-2 and colon cancer. Inflamm. Res. 47 Suppl 2 (1998) S112-S116
48. Tamura K., Sakurai T., and Kogo H. Relationship between prostaglandin E2 and vascular endothelial growth factor (VEGF) in angiogenesis in human vascular endothelial cells. Vasc. Pharmacol. 44 (2006) 411-416
49. Tong Q., Zheng L., Lin L., Li B., Wang D., Huang C., and Li D. VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K/Akt-NF-kappaB signaling pathway. Respir. Res. 7 (2006) 37
50. Tsujii M., Kawano S., and DuBois R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. U.S.A. 94 (1997) 3336-3340
51. Ushio-Fukai M., Tang Y., Fukai T., Dikalov S.I., Ma Y., Fujimoto M., Quinn M.T., Pagano P.J., Johnson C., and Alexander R.W. Novel role of gp91(phox)-containing NAD(P)H oxidase in vascular endothelial growth factor-induced signaling and angiogenesis. Circ. Res. 91 (2002) 1160-1167
52. van de Loosdrecht A.A., Nennie E., Ossenkoppele G.J., Beelen R.H., and Langenhuijsen M.M. Cell mediated cytotoxicity against U 937 cells by human monocytes and macrophages in a modified colorimetric MTT assay. J. Immunol. Methods 141 (1991) 15-22
53. Vane J.R., Bakhle Y.S., and Botting R.M. Cyclooxygenases 1 and 2. Annu. Rev. Pharmacol. Toxicol. 38 (1998) 97-120
54. Williams C.S., Tsujii M., Reese J., Dey S.K., and DuBois R.N. Host cyclooxygenase-2 modulates carcinoma growth. J. Clin. Invest. 105 (2000) 1589-1594
55. Yazawa K., Tsuno N.H., Kitayama J., Kawai K., Okaji Y., Asakage M., Sunami E., Kaisaki S., Hori N., Watanabe T., Takahashi K., and Nagawa H. Selective inhibition of cyclooxygenase (COX)-2 inhibits endothelial cell proliferation by induction of cell cycle arrest. Int. J. Cancer 113 (2005) 541-548
56. Yoshimoto K., Nishizawa S., Koshino H., Sato Y., Teramae N., and Maeda M. Assignment of hydrogen-bond structure in a ligand-nucleobase complex inside duplex DNA: combined use of quantum chemical calculations and 15N NMR experiments. Nucleic Acids Symp. Ser. (Oxf) 49 (2005) 255-256